Hydration, protein and the two failures that compound each other
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
Dosing
Page 20 of 31 of this archive, newest first.
Priming a pen is not optional
For licensed products the in-use period is established by stability data. For a peptide reconstituted at home there is no such data, and the honest answer is that nobody…
Non-responders, and the honest state of the evidence about them
The mechanism is well described. The variance is not.
Mexico pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What we would need to measure to explain the response distribution
The mechanism is well described. The variance is not.
Two-thirds back: the extension nobody expected to be the headline
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
Switzerland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Portugal guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Three weeks off is a fresh start, whether or not you want one
Concentrations fall by half a week, so a month away leaves a small fraction of steady state. Resuming at the previous dose presents the receptor with a step it has not seen…
Poland pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new the United Arab Emirates guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Antiemetics, laxatives and the thin literature underneath them
Constipation is the most tractable of the effects and the most consistently under-managed.
What the new South Africa guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
What changing your injection day does to tirzepatide exposure, and what it does not
What the pharmacokinetic data supports about dose timing, missed doses and interruption.
Every fortnight, every third week, seasonally: an unstudied practice
A great deal of practice has grown up around intermittent schedules. The randomised evidence for any of them is, as far as the Journal can establish, nil.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Errors ranked by how much dose they move
A pharmacist catches most of these in licensed practice. In this market there is no pharmacist, so the checks have to be structural.
Severity grading, and the gap between a grade and an experience
Almost every figure in circulation about tolerability comes from six publications. This is what they say.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.